- Also known as
- Thymalfasin · Tα1 · Ta1 · Thymosin α1 · TA-1 · Zadaxin
- Class
- Thymic immunomodulatory peptide
- Form
- Lyophilised powder in 5 mg and 10 mg vials
- Sizes
- 5 mg · 10 mg
- Storage, dry
- −20 °C, dry and dark
- Storage, mixed
- 2–8 °C, use within 28 days of mixing (as generally reported for reconstituted peptides)
- BAC water per size
- 5 mg: 2 mL · 10 mg: 2 mL
What is Thymosin Alpha-1?
Thymosin Alpha-1 is a thymic immunomodulatory peptide. Published work on it is in human. The name covers the same material written several ways in the literature, including Thymalfasin, Tα1 and Ta1. Its sequence is recorded as 28 amino acids with an acetylated N-terminus. The synthetic form is known as thymalfasin.. 5 of the 5 studies listed below are controlled trials in people. It appears in the literature as Thymalfasin, Tα1 and Ta1. Supplied as lyophilised powder in 5 mg and 10 mg vials, held in Canadian stock, for laboratory research. It is not a drug, and it is not supplied for use in a person or an animal.
What the research shows
| Study | Model | Dose used | Duration | Finding |
|---|---|---|---|---|
| Wu J et al.2025 · BMJ · PMID 39814420 | Human, multicentre double-blind randomised placebo-controlled phase 3 trial, adults with sepsis (n=1106 randomised; 1089 analysed) | Not stated in the abstract (subcutaneous injection) | Every 12 hours for seven days | 28-day all-cause mortality was 23.4% with thymosin α1 and 24.1% with placebo (hazard ratio 0.99, P=0.93). No secondary or safety outcome differed significantly; subgroup analyses suggested a possible difference by age and diabetes status. |
| Wu X et al.2018 · Expert Opin Biol Ther · PMID 30063860 | Human, multicentre randomised open-label trial, HBV-related compensated cirrhosis (n=690) | Not stated in the abstract (added to entecavir) | 52 weeks, after 26 weeks of entecavir; median follow-up 38.2 months | Cumulative incidence of liver decompensation, liver cancer (HCC) or death was similar between groups. HCC incidence during combination treatment was 1.7% versus 2.1% with entecavir alone; both therapies were well tolerated. |
| Maio M et al.2010 · J Clin Oncol · PMID 20194853 | Human, randomised trial with five arms, metastatic melanoma (n=488) | 1.6, 3.2 or 6.4 mg, combined with dacarbazine with or without interferon alfa | Primary end point at 12 months; observed for up to 24 months | The 3.2 mg arms had 10 and 12 tumour responses versus four in the control group. Median overall survival was 9.4 versus 6.6 months (hazard ratio 0.80, P=.08), and adding Tα1 did not add toxicity. |
| You J et al.2006 · World J Gastroenterol · PMID 17075991 | Human, randomised controlled trial versus interferon alpha, with a historical control group, HBeAg-positive chronic hepatitis B (n=62; 30 historical controls) | 1.6 mg subcutaneously | Twice a week for six months, then six months of follow-up | Complete response at the end of follow-up was 48.3% (14 of 29) with Tα1 versus 27.3% with interferon alpha, a difference that was not statistically significant (P>0.05); against historical controls it was significantly higher. No side effects appeared in the Tα1 group. |
| Saruc M et al.2003 · J Pharm Sci · PMID 12820143 | Human, non-randomised comparative study, HBeAg-negative chronic hepatitis B (n=52; 27 in the Tα1 group) | 1.6 mg subcutaneously, twice a week, combined with interferon alpha-2b | 26 weeks of combination, then 26 weeks of interferon alone; follow-up to 18 months after treatment | Sustained response was 74% in the Tα1 plus interferon group versus 40% and 53.3% in the comparison groups (p = 0.13). At 18 months after treatment, 71.4% of the Tα1 group kept their response versus 10% and 20% (p = 0.0003). |
What these studies don't show: Trials exist; their scope is narrower than it first appears. Participants are screened, many endpoints are proxies, and most trials end early. Results hold for the setting studied and no further. Testing establishes identity and purity; it is not evidence of an effect.
Every study links to its PubMed record. See all Thymosin Alpha-1 studies in the research library →
Thymosin Alpha-1 price in Canada: 5mg and 10mg vials
Buy Thymosin Alpha-1 in Canada in 2 vial sizes and a starter kit. Prices are in Canadian dollars, you pay by Interac e-Transfer or bank transfer, and orders are shipped from Canadian stock.
| Size | Price | Per mg |
|---|---|---|
| 5 mg | $41.00 | $8.20/mg |
| 10 mg | $52.00 | $5.20/mg |
Starter kit
Is Thymosin Alpha-1 available in Canada?
Thymosin Alpha-1 has no Drug Identification Number, which is how Health Canada marks a drug it has authorized. That means Health Canada has not assessed it for safety, efficacy or quality. It is stocked here as laboratory research material and for no use in a person or an animal. How Health Canada treats research peptides →
Side effects reported in studies
Each statement is tied to the study that reported it. Any tolerability finding below is quoted from the study that reported it. Human work of this size does not establish a safety profile.
Doses used in studies
Thymosin Alpha-1 FAQ
What is Thymosin Alpha-1?
Suppliers and the literature both list Thymosin Alpha-1 as a thymic immunomodulatory peptide. The published work on it is in human. Borealis Peptides supplies it as lyophilised powder in 5 mg and 10 mg vials for in-vitro laboratory research. Nothing here is a medicine; it is not for human or veterinary use. The studies behind it are listed on this page with the model each used and what the authors reported.
Where can I buy Thymosin Alpha-1 in Canada?
Borealis Peptides ships Thymosin Alpha-1 from Canadian stock to research and business addresses in Canada. It is held in 5 mg and 10 mg vials. Every batch is tested by HPLC and the certificate names the batch in your vial. Orders are accepted for laboratory research only.
Is Thymosin Alpha-1 legal in Canada?
Thymosin Alpha-1 has no Drug Identification Number, which is how Health Canada marks a drug it has authorized. That means Health Canada has not assessed it for safety, efficacy or quality. It is stocked here as laboratory research material and for no use in a person or an animal. Health Canada has said that "Research Use Only" labelling does not make a product legal to use in a person, so we treat it as a description of what the material is supplied for rather than a permission.
How much Thymosin Alpha-1 should I use?
Borealis Peptides gives no dosing, protocols or reconstitution volumes, and will not provide them on request. In laboratory work the amount follows from the study design, which a supplier cannot sensibly set. The figures on this page are what specific published studies used in their own models: a record of what was done, not a recommendation.
What human evidence is there for Thymosin Alpha-1?
Of the 5 studies cited, 5 are controlled trials in people and the rest are animal or cell work. Each row names its model, the amount used and what the authors reported, so the weight of each study can be judged directly rather than through a summary.
How long does Thymosin Alpha-1 keep?
Unopened, keep it at −20 °C in the dark. In solution it is kept at 2–8 °C. It travels at room temperature as a dry powder and goes cold on arrival. Keeping it dark and at a steady temperature matters more than how fast it arrived.
How is the purity of Thymosin Alpha-1 confirmed?
Identity and purity are confirmed by HPLC for each batch, not once per product. The certificate names the batch it belongs to, and that batch number is on the vial, so a result can be traced back to the exact material that produced it. Ask with your order number and we send it.
How does Thymosin Alpha-1 compare with TB-500 and Epitalon?
They are different compounds with different published records, and this site does not rank them. TB-500 and Epitalon have 7 cited studies and 8 cited studies on their page against 5 here. The useful comparison is between the two study tables and the models behind them.
Why is Thymosin Alpha-1 named in a Health Canada advisory?
Because it was among the peptides seized from sellers offering unauthorized injectable products online. The advisory concerns material sold for people to inject without authorization. Borealis Peptides supplies research material for laboratory use and sells nothing for injection or for any use in a person, which is the line that advisory draws.







